Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study

Código QR

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study

BackgroundNivolumab and pembrolizumab disrupt the programmed cell death-1 immune checkpoint and display promising efficacy and safety results in advanced hepatocellular carcinoma (HCC). However, the benefits remain limited. The preliminary results of lenvatinib (LEN) combined with immune checkpoint...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaozhun Huang, Lin Xu, Teng Ma, Xin Yin, Zhangkan Huang, Yihong Ran, Yong Ni, Xinyu Bi, Xu Che
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	hepatocellular carcinoma lenvatinib nivolumab pembrolizumab survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5a95c9e9aa9a43289ab143b53bdaa13b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
por: L. V. Bolotina
Publicado: (2020)

Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
por: Selina K. Wong, et al.
Publicado: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo
por: Ching-Hsuan Wu, et al.
Publicado: (2022)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Jie Zhu, et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Toshiki Ogiwara, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
por: Soji Toda, et al.
Publicado: (2021)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
por: Skubalova Z, et al.
Publicado: (2021)

The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
por: Katarína Vavrová, et al.
Publicado: (2022)

Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
por: Elena A. Demina
Publicado: (2021)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale MB, et al.
Publicado: (2017)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Qiyi Zhang, et al.
Publicado: (2021)

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
por: Lang D, et al.
Publicado: (2020)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo Geng-wei, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma
por: Bin Chai, et al.
Publicado: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)

Identification of the Pyroptosis-Related Gene Signature for Overall Survival Prediction in Patients With Hepatocellular Carcinoma
por: Shuang Liu, et al.
Publicado: (2021)

Efficacy of radiofrequency ablation versus laparoscopic liver resection for hepatocellular carcinoma in China: a comprehensive meta-analysis
por: Zhijun Li, et al.
Publicado: (2021)

Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China
por: Jing Wu, et al.
Publicado: (2021)

Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum]
por: Tai Y, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Youwen Zhu, et al.
Publicado: (2021)

Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
por: Yusuke Johira, et al.
Publicado: (2021)

Surgical Treatment of Postoperative Abdominal Metastases of Hepatocellular Carcinoma: 10-Year Experience in a Single Center
por: Fang J, et al.
Publicado: (2021)

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies
por: Gkiala A, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Yuanyi Cai, et al.
Publicado: (2021)

Clinical outcomes of surgical resection versus radiofrequency ablation in very-early‐stage hepatocellular carcinoma: a propensity score matching analysis
por: Yuan-Chen Li, et al.
Publicado: (2021)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Yuki Katsumata, et al.
Publicado: (2021)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Pei-Yi Chu, et al.
Publicado: (2021)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Masatoshi Kudo
Publicado: (2021)

Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Han Q, et al.
Publicado: (2021)

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
por: Giuseppe Cabibbo, et al.
Publicado: (2021)

A Minimal Subset of Seven Genes Associated with Tumor Hepatocyte Differentiation Predicts a Poor Prognosis in Human Hepatocellular Carcinoma
por: Matthis Desoteux, et al.
Publicado: (2021)

Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies
por: XinYue Zhang, et al.
Publicado: (2021)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Artem Gusak, et al.
Publicado: (2021)